Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
OTCMKTS:BAYRY

Bayer Aktiengesellschaft 11/12/2024 Earnings Results & Report

Bayer Aktiengesellschaft logo
$12.56 +0.23 (+1.87%)
As of 09:54 AM Eastern

Bayer Aktiengesellschaft missed analyst earnings expectations in results released November 12, 2024. The company reported EPS of $0.07 versus the $0.17 consensus estimate, while revenue was $10.96 billion.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Report Date
Time
Before Market Opens

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.07
Consensus EPS
$0.17
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$10.96 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Earnings FAQ

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) reported earnings of $0.07 per share for the quarter, missing the consensus estimate of $0.17. The report was announced on Tuesday, November 12, 2024.

Bayer Aktiengesellschaft reported revenue of $10.96 billion for the quarter.

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bayer Aktiengesellschaft on the company's earnings history page.

Bayer Aktiengesellschaft Earnings Headlines

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
October 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261007322202/en/Bayer-to-Present-New-Cardiac-Amyloidosis-and-Heart-Failure-Data-at-the-Heart-Failure-Society-of-America-HFSA-Annual-Scientific-Meeting/
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
October 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261007583229/en/u.s.-fda-accepts-bayer%e2%80%99s-supplemental-new-drug-application-for-kerendia%c2%ae-finerenone-to-treat-adults-with-chronic-kidney-disease-ckd-without-diabetes/
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
October 15 at 1:00 AM  |  Investors Alley (Ad)
Bayer’s Real‑World Prostate Cancer Study Signals Key Trends for Treatment Adoption in Canada
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bayers-realworld-prostate-cancer-study-signals-key-trends-for-treatment-adoption-in-canada?utm_source=marketbeat.com&utm_medium=referral
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
October 2, 2026  |  wsj.comhttps://www.wsj.com/health/pharma/bayer-to-invest-2-2-billion-in-u-s-pharma-manufacturing-expansion-ec038b86
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261002202241/en/bayer-to-invest-2.2-billion-u.s.-dollars-in-a-new-manufacturing-site-in-the-united-states/
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin. The Crop Science business supplies seeds, crop protection products and digital agricultural solutions for farmers and other agricultural customers.

Founded in 1863, Bayer is headquartered in Leverkusen, Germany, and serves customers in markets around the world. The company expanded its agricultural operations through the acquisition of Monsanto in 2018, adding seed and crop protection businesses to its portfolio. Bayer is led by Chief Executive Officer Bill Anderson, who assumed the role in June 2023.

View Bayer Aktiengesellschaft Profile
Earnings Tools